Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥ 5.5 mmol/L: pooled analysis from two phase 3 trials

[1]  E. Wu,et al.  The Cost of Hyperkalemia in the United States , 2017, Kidney international reports.

[2]  B. Pitt,et al.  Association of Serum Potassium with All-Cause Mortality in Patients with and without Heart Failure, Chronic Kidney Disease, and/or Diabetes , 2017, American Journal of Nephrology.

[3]  N. Oestreicher,et al.  Clinical and Economic Impact of Hyperkalemia in Patients with Chronic Kidney Disease and Heart Failure. , 2017, Journal of managed care & specialty pharmacy.

[4]  Jiwei Zhao,et al.  Systematic Review and Meta‐Analysis of Patiromer and Sodium Zirconium Cyclosilicate: A New Armamentarium for the Treatment of Hyperkalemia , 2017, Pharmacotherapy.

[5]  A. Mebazaa,et al.  Emergency management of severe hyperkalemia: Guideline for best practice and opportunities for the future. , 2016, Pharmacological research.

[6]  M. Kosiborod,et al.  Pharmacodynamics and pharmacokinetics of sodium zirconium cyclosilicate [ZS-9] in the treatment of hyperkalemia , 2016, Expert opinion on drug metabolism & toxicology.

[7]  S. Brunelli,et al.  Association between Serum Potassium and Outcomes in Patients with Reduced Kidney Function. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[8]  M. B. Bridgeman,et al.  Potassium-Binding Agents for the Clinical Management of Hyperkalemia. , 2016, P & T : a peer-reviewed journal for formulary management.

[9]  M. Belz,et al.  Sodium polystyrene sulfonate for the treatment of acute hyperkalemia: a retrospective study. , 2016, Clinical nephrology.

[10]  C. Kovesdy.  Management of Hyperkalemia: An Update for the Internist. , 2015, The American journal of medicine.

[11]  J. Dunn,et al.  The burden of hyperkalemia in patients with cardiovascular and renal disease. , 2015, The American journal of managed care.

[12]  M. Freeman,et al.  Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia , 2015, Kidney international.

[13]  Josh Batterink,et al.  Effectiveness of Sodium Polystyrene Sulfonate for Short-Term Treatment of Hyperkalemia. , 2015, The Canadian journal of hospital pharmacy.

[14]  M. Freeman,et al.  Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial. , 2015, JAMA.

[15]  M. Kosiborod,et al.  Sodium zirconium cyclosilicate for urgent therapy of severe hyperkalemia. , 2015, The New England journal of medicine.

[16]  P. Lavin,et al.  A phase 2 study on the treatment of hyperkalemia in patients with chronic kidney disease suggests that the selective potassium trap, ZS-9, is safe and efficient , 2015, Kidney international.

[17]  P. Lavin,et al.  Sodium zirconium cyclosilicate in hyperkalemia. , 2015, The New England journal of medicine.

[18]  G. Bakris,et al.  Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. , 2015, The New England journal of medicine.

[19]  M. Nuttall,et al.  Characterization of Structure and Function of ZS-9, a K+ Selective Ion Trap , 2014, PloS one.

[20]  P. Lavin,et al.  Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial. , 2014, JAMA.

[21]  Han‐Chieh Lin,et al.  Nonpeptic ulcer, nonvariceal gastrointestinal bleeding in hemodialysis patients. , 2013, The American journal of medicine.

[22]  Jeffrey Perl,et al.  Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. , 2013, The American journal of medicine.

[23]  Y. Oh,et al.  Severe hyperkalemia requiring hospitalization: predictors of mortality , 2012, Critical Care.

[24]  M. Mendu,et al.  Association between hyperkalemia at critical care initiation and mortality , 2012, Intensive Care Medicine.

[25]  R. Sterns,et al.  Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? , 2010, Journal of the American Society of Nephrology : JASN.

[26]  M. Zhan,et al.  The frequency of hyperkalemia and its significance in chronic kidney disease. , 2009, Archives of internal medicine.

[27]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[28]  THE ROYAL MELBOURNE HOSPITAL , 1951 .